Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
223 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Osteosarcoma - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Osteosarcoma - Pipeline Review, H2 2016', provides an overview of the Osteosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Osteosarcoma - The report reviews pipeline therapeutics for Osteosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Osteosarcoma therapeutics and enlists all their major and minor projects - The report assesses Osteosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Osteosarcoma Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Osteosarcoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Osteosarcoma Overview 11 Therapeutics Development 12 Pipeline Products for Osteosarcoma - Overview 12 Pipeline Products for Osteosarcoma - Comparative Analysis 13 Osteosarcoma - Therapeutics under Development by Companies 14 Osteosarcoma - Therapeutics under Investigation by Universities/Institutes 16 Osteosarcoma - Pipeline Products Glance 17 Clinical Stage Products 17 Early Stage Products 18 Osteosarcoma - Products under Development by Companies 19 Osteosarcoma - Products under Investigation by Universities/Institutes 20 Osteosarcoma - Companies Involved in Therapeutics Development 21 Advaxis, Inc. 21 Amgen Inc. 22 AVEO Pharmaceuticals, Inc. 23 Bayer AG 24 Bellicum Pharmaceuticals, Inc. 25 Celldex Therapeutics, Inc. 26 CytRx Corporation 27 Eleison Pharmaceuticals LLC 28 Exelixis, Inc. 29 Isofol Medical AB 30 MediaPharma s.r.l. 31 Merck & Co., Inc. 32 Merrimack Pharmaceuticals, Inc. 33 Netris Pharma S.A.S. 34 Novartis AG 35 Oncolys BioPharma Inc 36 Pfizer Inc. 37 Shionogi & Co., Ltd. 38 Teijin Pharma Limited 39 United Therapeutics Corporation 40 Osteosarcoma - Therapeutics Assessment 41 Assessment by Monotherapy Products 41 Assessment by Target 42 Assessment by Mechanism of Action 45 Assessment by Route of Administration 48 Assessment by Molecule Type 50 Drug Profiles 52 3D-QM - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 3D-QMS - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 ADXS-HER2 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 aldoxorubicin hydrochloride - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 AM-7209 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 AU-101 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 AV-203 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 axitinib - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 cabozantinib s-malate - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 celyvir - Drug Profile 106 Product Description 106 Mechanism Of Action 106 R&D Progress 106 CGS-200 - Drug Profile 107 Product Description 107 Mechanism Of Action 107 R&D Progress 107 cisplatin SR - Drug Profile 108 Product Description 108 Mechanism Of Action 108 R&D Progress 108 dihydroartemisinin - Drug Profile 110 Product Description 110 Mechanism Of Action 110 R&D Progress 110 dinutuximab - Drug Profile 111 Product Description 111 Mechanism Of Action 111 R&D Progress 111 everolimus - Drug Profile 113 Product Description 113 Mechanism Of Action 113 R&D Progress 113 glembatumumab vedotin - Drug Profile 125 Product Description 125 Mechanism Of Action 125 R&D Progress 125 irinotecan hydrochloride - Drug Profile 130 Product Description 130 Mechanism Of Action 130 R&D Progress 130 ligerin - Drug Profile 141 Product Description 141 Mechanism Of Action 141 R&D Progress 141 LLL-12 - Drug Profile 142 Product Description 142 Mechanism Of Action 142 R&D Progress 142 Modufolin - Drug Profile 143 Product Description 143 Mechanism Of Action 143 R&D Progress 143 Monoclonal Antibody for Osteosarcoma - Drug Profile 145 Product Description 145 Mechanism Of Action 145 R&D Progress 145 Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 146 Product Description 146 Mechanism Of Action 146 R&D Progress 146 Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile 147 Product Description 147 Mechanism Of Action 147 R&D Progress 147 MPE-8.3 - Drug Profile 149 Product Description 149 Mechanism Of Action 149 R&D Progress 149 NP-137 - Drug Profile 150 Product Description 150 Mechanism Of Action 150 R&D Progress 150 OBP-702 - Drug Profile 151 Product Description 151 Mechanism Of Action 151 R&D Progress 151 Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer - Drug Profile 152 Product Description 152 Mechanism Of Action 152 R&D Progress 152 pazopanib hydrochloride - Drug Profile 153 Product Description 153 Mechanism Of Action 153 R&D Progress 153 pembrolizumab - Drug Profile 160 Product Description 160 Mechanism Of Action 160 R&D Progress 160 Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 191 Product Description 191 Mechanism Of Action 191 R&D Progress 191 radium Ra 223 dichloride - Drug Profile 193 Product Description 193 Mechanism Of Action 193 R&D Progress 193 RSF-101 - Drug Profile 202 Product Description 202 Mechanism Of Action 202 R&D Progress 202 S-588410 - Drug Profile 203 Product Description 203 Mechanism Of Action 203 R&D Progress 203 SEN-461 - Drug Profile 205 Product Description 205 Mechanism Of Action 205 R&D Progress 205 Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma - Drug Profile 206 Product Description 206 Mechanism Of Action 206 R&D Progress 206 Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile 207 Product Description 207 Mechanism Of Action 207 R&D Progress 207 T-2GES - Drug Profile 208 Product Description 208 Mechanism Of Action 208 R&D Progress 208 Vaccine for Osteosarcoma - Drug Profile 209 Product Description 209 Mechanism Of Action 209 R&D Progress 209 Osteosarcoma - Dormant Projects 210 Osteosarcoma - Discontinued Products 212 Osteosarcoma - Product Development Milestones 213 Featured News & Press Releases 213 Apr 28, 2016: FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma 213 Apr 20, 2016: Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin at the AACR Annual Meeting 2016 213 Apr 13, 2016: Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform 214 Mar 23, 2016: Advaxis Hosts Research Reception to Review Late-Breaking ADXS-HER2 at AACR Abstract 215 Mar 21, 2016: Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research 215 Mar 16, 2016: Merrimack to Present on ONIVYDE (irinotecan liposome injection) at the 2016 American Association for Cancer Research Annual Meeting 216 Jan 19, 2016: Advaxis Expands Intellectual Property for Lm Technology Platform 216 Dec 01, 2015: Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma 217 Nov 30, 2015: CapGenesis Files Five Orphan Drug Designation Requests with the FDA and EMA for CGS-200 as a Topical Analgesic 217 Jul 21, 2015: Advaxis Expands Intellectual Property for Lm Technology Platform in HER2 218 May 04, 2015: CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 219 May 01, 2015: Eleison Announces Successful Completion of Stage 1 of its Phase II Trial of ILC (Inhaled Lipid-complexed Cisplatin) for Pediatric Bone Cancer 220 Apr 28, 2015: Advaxis Enhances Lm-LLO Cancer Immunotherapy Intellectual Property With USPTO Patent Addressing ADXS-HER2 220 Nov 04, 2014: Advaxis to Present Data of ADXS-cHER2 at the Society for Immunotherapy of Cancer 29th Annual Meeting 221 Appendix 222 Methodology 222 Coverage 222 Secondary Research 222 Primary Research 222 Expert Panel Validation 222 Contact Us 222 Disclaimer 223
List of Tables
Number of Products under Development for Osteosarcoma, H2 2016 12 Number of Products under Development for Osteosarcoma - Comparative Analysis, H2 2016 13 Number of Products under Development by Companies, H2 2016 15 Number of Products under Investigation by Universities/Institutes, H2 2016 16 Comparative Analysis by Clinical Stage Development, H2 2016 17 Comparative Analysis by Early Stage Development, H2 2016 18 Products under Development by Companies, H2 2016 19 Products under Investigation by Universities/Institutes, H2 2016 20 Osteosarcoma - Pipeline by Advaxis, Inc., H2 2016 21 Osteosarcoma - Pipeline by Amgen Inc., H2 2016 22 Osteosarcoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 23 Osteosarcoma - Pipeline by Bayer AG, H2 2016 24 Osteosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 25 Osteosarcoma - Pipeline by Celldex Therapeutics, Inc., H2 2016 26 Osteosarcoma - Pipeline by CytRx Corporation, H2 2016 27 Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H2 2016 28 Osteosarcoma - Pipeline by Exelixis, Inc., H2 2016 29 Osteosarcoma - Pipeline by Isofol Medical AB, H2 2016 30 Osteosarcoma - Pipeline by MediaPharma s.r.l., H2 2016 31 Osteosarcoma - Pipeline by Merck & Co., Inc., H2 2016 32 Osteosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 33 Osteosarcoma - Pipeline by Netris Pharma S.A.S., H2 2016 34 Osteosarcoma - Pipeline by Novartis AG, H2 2016 35 Osteosarcoma - Pipeline by Oncolys BioPharma Inc, H2 2016 36 Osteosarcoma - Pipeline by Pfizer Inc., H2 2016 37 Osteosarcoma - Pipeline by Shionogi & Co., Ltd., H2 2016 38 Osteosarcoma - Pipeline by Teijin Pharma Limited, H2 2016 39 Osteosarcoma - Pipeline by United Therapeutics Corporation, H2 2016 40 Assessment by Monotherapy Products, H2 2016 41 Number of Products by Stage and Target, H2 2016 43 Number of Products by Stage and Mechanism of Action, H2 2016 46 Number of Products by Stage and Route of Administration, H2 2016 49 Number of Products by Stage and Molecule Type, H2 2016 51 Osteosarcoma - Dormant Projects, H2 2016 210 Osteosarcoma - Dormant Projects (Contd..1), H2 2016 211 Osteosarcoma - Discontinued Products, H2 2016 212
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
